RLX Technology Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? RLX Technology Inc trades at $1.72 (market cap $2.10B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 11.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 34 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| RLX | ROIV | |
|---|---|---|
Market Cap | $2.10B | $24.72B |
Volume | 1,079,706 | 6,279,442 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $41.81 |
52-Week Low | $1.68 | $16.04 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $832.26M | $20.99B |
Dividend Yield | 5.81% | — |
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.73, near its 52-week low of $1.67, with bearish technical signals from moving averages. The company reported strong 2025 fundamentals with $921.87M net income and 21.87% net margin, though recent quarters show earnings misses. International expansion drives growth, with 70% of revenue now from overseas markets following European acquisitions.
The stock presents a value opportunity with discounted valuation multiples (P/E 15.46, P/B 0.91) but faces headwinds from recent earnings underperformance and bearish technical momentum. Key risks include margin compression and regulatory uncertainty in the e-vapor industry, while analyst sentiment remains neutral with 100% hold rating.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →